1. Home
  2. RGEN vs LNTH Comparison

RGEN vs LNTH Comparison

Compare RGEN & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGEN
  • LNTH
  • Stock Information
  • Founded
  • RGEN 1981
  • LNTH 1956
  • Country
  • RGEN United States
  • LNTH United States
  • Employees
  • RGEN N/A
  • LNTH N/A
  • Industry
  • RGEN Medical/Dental Instruments
  • LNTH Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • RGEN Health Care
  • LNTH Health Care
  • Exchange
  • RGEN Nasdaq
  • LNTH Nasdaq
  • Market Cap
  • RGEN 8.0B
  • LNTH 7.5B
  • IPO Year
  • RGEN N/A
  • LNTH 2015
  • Fundamental
  • Price
  • RGEN $126.50
  • LNTH $81.24
  • Analyst Decision
  • RGEN Buy
  • LNTH Strong Buy
  • Analyst Count
  • RGEN 12
  • LNTH 5
  • Target Price
  • RGEN $172.67
  • LNTH $133.80
  • AVG Volume (30 Days)
  • RGEN 815.5K
  • LNTH 1.4M
  • Earning Date
  • RGEN 04-29-2025
  • LNTH 05-07-2025
  • Dividend Yield
  • RGEN N/A
  • LNTH N/A
  • EPS Growth
  • RGEN N/A
  • LNTH N/A
  • EPS
  • RGEN N/A
  • LNTH 3.53
  • Revenue
  • RGEN $650,429,000.00
  • LNTH $1,536,699,000.00
  • Revenue This Year
  • RGEN $13.93
  • LNTH $4.96
  • Revenue Next Year
  • RGEN $14.35
  • LNTH $10.25
  • P/E Ratio
  • RGEN N/A
  • LNTH $23.00
  • Revenue Growth
  • RGEN 4.88
  • LNTH 12.53
  • 52 Week Low
  • RGEN $102.97
  • LNTH $74.34
  • 52 Week High
  • RGEN $182.52
  • LNTH $126.89
  • Technical
  • Relative Strength Index (RSI)
  • RGEN 44.61
  • LNTH 32.82
  • Support Level
  • RGEN $123.10
  • LNTH $77.01
  • Resistance Level
  • RGEN $135.47
  • LNTH $83.60
  • Average True Range (ATR)
  • RGEN 6.98
  • LNTH 3.77
  • MACD
  • RGEN -0.97
  • LNTH -2.21
  • Stochastic Oscillator
  • RGEN 25.20
  • LNTH 13.26

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

About LNTH Lantheus Holdings Inc.

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

Share on Social Networks: